This study included six studies (two for breast cancer, and one each for acute myeloid leukemia, hepatocellular carcinoma, lung cancer and gastric cancer) that explored interaction effects between TP53 Arg72Pro and MDM2 SNP309. This evidence concerns the gene MDM2 and hepatocellular carcinoma.